Loss of quality of life associated with genital warts: Baseline analyses from a prospective study

Sexually Transmitted Infections

Volumn 87, Issue 3, 2011, Pages 209-215

  Sénécal, Martin ^a   Brisson, Marc ^b,c   Maunsell, Elizabeth ^b,c   Ferenczy, Alex ^d,e   Franco, Eduardo L ^d   Ratnam, Sam ^f   Coutlée, François ^g   Palefsky, Joel M ^h   Mansi, James A ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f Newfoundland and Labrador Public Health Laboratory   (Canada)

^g NOTRE DAME HOSPITAL   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY; ARTICLE; CANADA; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; EQ 5D; FEMALE; FOLLOW UP; GENDER; GENITAL PAIN; HEALTH STATUS; HETEROSEXUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE;

EID: 79953096431     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sti.2009.039982     Document Type: Article

References (31)

1. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85. (Pubitemid 38924707)
2. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
3. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805-14.
4. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995;33:2058-63.
5. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8. (Pubitemid 127695953)
6. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70 000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007;196:1447-54. (Pubitemid 351411979)
7. Grulich AE, de Visser RO, Smith AM, et al. Sex in Australia: knowledge about sexually transmissible infections and blood-borne viruses in a representative sample of adults. Aust NZ J Public Health 2003;27:230-3. (Pubitemid 36526896)
8. Franco EL, Villa L, Richardson H, et al. Chapter 2: epidemiology of cervical human papillomavirus infection. In: Franco EL, Monsonego J, eds. New developments in cervical cancer screening and prevention. Oxford: Blackwell Science Ltd, 1997:14-22.
9. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005;23:2470-6.
10. Jeynes C, Chung MC, Challenor R. 'Shame on you'-the psychosocial impact of genital warts. Int J STD AIDS 2009;20:557-60.
11. Marra C, Ogilvie G, Gastonguay L, et al. Patients with genital warts have a decreased quality of life. Sex Transm Dis 2009;36:258-60.
12. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571-8. (Pubitemid 28474812)
13. Persson G, Dahlof LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993;20:10-13. (Pubitemid 23082231)
14. Pirotta M, Ung L, Stein A, et al. The psychosocial burden of HPV-related disease and screening interventions. Sex Transm Infect 2009;85:508-13.
15. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008;84:161-6. (Pubitemid 351871484)
16. Mast TC, Zhu X, Demuro-Mercon C, et al. Development and psychometric properties of the HPV impact profile (HIP) to assess the psychosocial burden of HPV. Curr Med Res Opin 2009;25:2609-19.
17. Rohan T, Mann V, McLaughlin J, et al. PCR-detected genital papillomavirus infection: prevalence and association with risk factors for cervical cancer. Int J Cancer 1991;49:856-60.
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108. (Pubitemid 127453463)
19. Johnson JA, Pickard AS. Comparison of the EQ-5D and SF-12 health surveys in a general population survey in Alberta, Canada. Med Care 2000;38:115-21.
20. Luo N, Johnson JA, Shaw JW, et al. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 2005;43:1078-86. (Pubitemid 41587593)
21. Baldwin SB, Wallace DR, Papenfuss MR, et al. Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis 2004;31:601-7. (Pubitemid 39281832)
22. Munoz N, Kato I, Bosch FX, et al. Risk factors for HPV DNA detection in middle-aged women. Sex Transm Dis 1996;23:504-10. (Pubitemid 26391576)
23. Rousseau MC, Franco EL, Villa LL, et al. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev 2000;9:469-76. (Pubitemid 30313889)
24. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. Can Med Assoc J 2000;163:503-8.
25. Wen LM, Estcourt CS, Simpson JM, et al. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 1999;75:312-16.
26. Drummond MF, O'Brien B, Stoddart GL, et al. Cost-utility analyses. Methods for the economic evaluation of health care programmes. 2nd edn. New York: Oxford University Press, 1997:139-204.
27. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 2003;36:1397-403. (Pubitemid 36702873)
28. Monsonego J, Breugelmans JG, Bouee S, et al. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France] (In French). Gynecol Obstet Fertil 2007;35:107-13.
29. Marra F, Ogilvie G, Colley L, et al. Epidemiology and costs associated with genital warts in Canada. Sex Transm Infect 2008;85:111-15.
30. Kliewer EV, Demers AA, Elliott L, et al. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. Sex Transm Dis 2009;36:380-6.
31. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8. (Pubitemid 40271061)